Anticoagulation Therapy

Introduction

Anticoagulation therapy, such as rivaroxaban, is used for the prevention and treatment of thromboembolic disorders, including atrial fibrillation, deep vein thrombosis, and pulmonary embolism 1, 2

The European Society of Cardiology recommends avoiding rivaroxaban in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, such as Child-Pugh B and C liver cirrhosis 3
The European Society of Cardiology also recommends avoiding rivaroxaban in dialysis patients 3
The International Society on Thrombosis and Haemostasis recommends avoiding concomitant use with strong inhibitors of both CYP3A4 and P-glycoprotein, including azole antimycotics and HIV protease inhibitors 4, 5

The American College of Physicians recommends dose reduction from 20 mg once daily to 15 mg once daily for patients with moderate to severe renal impairment (CrCl 15-49 mL/min) 4
The European Society of Cardiology recommends avoiding rivaroxaban in patients with severe renal impairment (CrCl <15 mL/min) for VTE indication 6
Rivaroxaban is partially eliminated via the kidneys, with approximately 33-35% of the active drug cleared through renal excretion, making renal function an important consideration when prescribing this medication 4, 3
The European Heart Rhythm Association recommends discontinuing rivaroxaban when a patient's estimated glomerular filtration rate (eGFR) falls below 15 mL/min, as it is not approved for use in patients with end-stage renal disease (eGFR <15 mL/min) 3

The International Society on Thrombosis and Haemostasis recommends avoiding use in patients with elevated liver enzymes >2 times the upper limit of normal 4

The National Comprehensive Cancer Network recommends using direct oral anticoagulants with caution in patients with gastric or gastroesophageal tumors due to increased risk of hemorrhage 7
Elderly patients (>75 years) with renal dysfunction should use rivaroxaban with caution, as advised by the National Comprehensive Cancer Network 8
Patients weighing less than 50 kg should also use rivaroxaban with caution, according to the National Comprehensive Cancer Network 8
Rivaroxaban should be used with caution in patients with moderate renal impairment (CrCl 30-50 mL/min), as advised by the National Comprehensive Cancer Network 8 and the American Academy of Family Physicians 9
Rivaroxaban should be avoided in patients with severe renal impairment (CrCl <30 mL/min), as recommended by the National Comprehensive Cancer Network 8 and the American Academy of Family Physicians 9

For patients with normal to moderate renal impairment (eGFR ≥50 mL/min), the standard dose of rivaroxaban is 20 mg once daily with food, as recommended by the American Academy of Family Physicians 9
For patients with moderate to severe renal impairment (eGFR 15-49 mL/min), a reduced dose of 15 mg once daily with food is recommended 4
Consider low-dose rivaroxaban (2.5 mg twice daily) plus low-dose aspirin for secondary prevention in patients with both coronary artery disease/peripheral artery disease and history of stroke, which reduces major adverse cardiovascular events but increases bleeding risk 10

The European Society of Cardiology recommends renal function assessment using creatinine clearance calculation (Cockcroft-Gault formula preferred) 3
The International Society on Thrombosis and Haemostasis recommends liver function tests (transaminases, bilirubin), complete blood count, and assessment for potential drug interactions 4
For management of major bleeding, consider prothrombin complex concentrate (PCC) at 25-50 U/kg 11
Discontinuation of rivaroxaban increases the risk of thrombosis; therefore, transitioning to another anticoagulant should be considered if stopping, and abrupt discontinuation without alternative anticoagulation should be avoided 9
Unlike warfarin, routine coagulation monitoring (PT/INR) is not required or recommended for rivaroxaban, as stated by the American College of Chest Physicians 5

The American Heart Association/American Stroke Association recommends starting oral anticoagulation, such as rivaroxaban, within 2 weeks of acute ischemic stroke, individualized based on infarct size and bleeding risk 1
Rivaroxaban is indicated for secondary prevention in patients with prior ischemic stroke due to atrial fibrillation, as shown in the ROCKET AF trial where rivaroxaban was non-inferior to warfarin in patients with prior stroke history 2
Delay initiation of rivaroxaban to around 14 days post-stroke for patients with large infarcts, and avoid very early anticoagulation (<48 hours) 1
Starting rivaroxaban too early after a large stroke increases the risk of hemorrhagic transformation 1
Rivaroxaban carries an increased risk of bleeding compared to antiplatelet therapy alone, and regular monitoring of renal function is essential, especially in patients with fluctuating renal function [1] [2]
In patients with prior stroke, the primary safety endpoint (bleeding) occurred in 3.5% of rivaroxaban users versus 3.9% of warfarin users 2